Commercial health plans’ transition from copays to coinsurance and deductibles has increased patient out-of-pocket costs for brand medicines
By Gabby Migliara | August 6, 2020
A decade ago, most patients paid only copays for brand medicines. But in recent years, use of deductibles and coinsurance in commercial health plans has skyrocketed. According to a recent IQVIA...
Read More
Four things to know about the IQVIA “Medicine Spending and Affordability in the U.S.” report
By Katie Koziara | August 5, 2020
Today, IQVIA released a new report, Medicine Spending and Affordability in the U.S., providing context on medicine price and spending trends and patient out-of-pocket costs. The report highlights...
Read More
ICYMI: The latest as America’s biopharmaceutical companies work to beat COVID-19
By Andrew Powaleny | August 4, 2020
America’s biopharmaceutical companies are working around the clock to defeat COVID-19, a disease caused by a novel strain of the coronavirus. The biopharmaceutical industry continues to make...
Read More
New data show commercially insured patients face increasingly high cost sharing for brand medicines
By Gabby Migliara | July 30, 2020
New data show deductibles and coinsurance result in high out-of-pocket spending for commercially insured patients taking brand medicines. IQVIA analyzed trends in cost sharing across seven therapy...
Read More
Executive order threatens R&D when we need it most to fight COVID-19
By Nicole Longo | July 30, 2020
In case you missed it, President Trump recently signed executive orders that would implement sweeping changes to the biopharmaceutical industry. While his intention may have been to help Americans...
Read More
Medicare’s 55th anniversary: Celebrating the success of Part D
By Tom Wilbur | July 30, 2020
Today, we are excited to bring you a special edition of our Medicare Catalyst series in honor of Medicare’s 55th anniversary. On this date in 1965, President Lyndon B. Johnson signed into law...
Read More
Payers subject 80% of new RA and MS patients to utilization management restrictions
By Gabby Migliara | July 22, 2020
A new analysis from IQVIA shows that in 2018, 80% of commercially insured patients attempting to fill a new prescription for a rheumatoid arthritis (RA) or multiple sclerosis (MS) medicine...
Read More
The latest: What they are saying: intellectual property protections critical as we work to defeat COVID-19
By Tom Wilbur | July 22, 2020
America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient...
Read More
PhRMA submits comments to CMS on Medicaid proposed rule
By Nicole Longo | July 21, 2020
In response to the Centers for Medicare and Medicaid Services’ (CMS) proposed rule regarding changes to Medicaid, PhRMA provided feedback on how the changes included would have widespread impacts...
Read More
New report shows more than 400 medicines and vaccines in development to tackle infectious diseases, including COVID-19
By Andrew Powaleny | July 21, 2020
Throughout history, infectious diseases caused by pathogens such as bacteria or viruses have taken a devastating toll on the lives and security of people around the world. With the ongoing...
Read More
Medicare Monday (100)
340B Spotlight (43)
Cost & Consequence (0)
